Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease

Hidekazu Tomimoto, Ichiro Akiguchi, Ryo Ohtani, Hideo Yagi, Satoshi Ogura, Hideaki Wakita

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

The blood coagulation system has been shown to be activated in subacute exacerbations of Binswanger disease (BD). In our previous study, the antithrombin drug argatroban ameliorated the neurological exacerbations in a BD patient with antiphospholipid antibody syndrome. We have further examined the therapeutic efficacy of argatroban in 3 BD patients with subacute exacerbations, but without any immune-mediated prothrombotic complications. In 1 out of these 4 patients, treatment with sodium ozagrel, an antiplatelet drug was applied, but was ineffective. In all patients, argatroban treatment reduced the levels of the hemostatic markers, with a corresponding improvement in cognitive dysfunction and gait disorders. These results suggest that the antithrombin effect is true also for BD patients not compromised by the immune-mediated prothrombotic condition.

Original languageEnglish
Pages (from-to)966-969
Number of pages4
JournalInternal Medicine
Volume39
Issue number11
DOIs
Publication statusPublished - 11-2000
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint Dive into the research topics of 'Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease'. Together they form a unique fingerprint.

Cite this